Revolution Medicines to Host Investor Conference Call on Positive RASolute 302 Results Following 2026 ASCO Presentation

Rhea-AI Summary

Revolution Medicines (Nasdaq: RVMD) will host a live investor webcast on Sunday, May 31, 2026 at 7:00 p.m. ET to discuss positive Phase 3 RASolute 302 results for daraxonrasib in previously treated metastatic pancreatic ductal adenocarcinoma (PDAC), following presentation at the 2026 ASCO Annual Meeting.

The webcast and a replay (available for at least 14 days) can be accessed via the company’s investor relations events and presentations webpage.

News Market Reaction – RVMD

-1.41%

-1.41% Session close to close

In the May 22 session, RVMD declined 1.41%, reflecting a mild negative market reaction.

Data tracked by StockTitan Argus on the day of publication.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

REDWOOD CITY, Calif., May 21, 2026 (GLOBE NEWSWIRE) -- Revolution Medicines, Inc. (Nasdaq: RVMD), a late-stage clinical oncology company developing targeted therapies for patients with RAS-addicted cancers, today announced that members of Revolution Medicines’ senior management team will host a webcast on Sunday, May 31 at 7:00 pm ET to discuss positive results from the Phase 3 RASolute 302 clinical trial evaluating daraxonrasib in patients with previously treated metastatic pancreatic ductal adenocarcinoma (PDAC) following presentation of the data during the Plenary Session at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting.

To listen to the live webcast, or access the archived webcast, please visit: https://ir.revmed.com/events-and-presentations. Following the live webcast, a replay will be available on the company’s website for at least 14 days.

About Revolution Medicines, Inc.
Revolution Medicines is a late-stage clinical oncology company developing novel targeted therapies for patients with RAS-addicted cancers. The company’s R&D pipeline comprises RAS(ON) inhibitors designed to suppress diverse oncogenic variants of RAS proteins. The company’s RAS(ON) inhibitors daraxonrasib (RMC-6236), a RAS(ON) multi-selective inhibitor; elironrasib (RMC-6291), a RAS(ON) G12C-selective inhibitor; zoldonrasib (RMC-9805), a RAS(ON) G12D-selective inhibitor; and RMC-5127, a RAS(ON) G12V-selective inhibitor, are currently in clinical development. Additional development opportunities in the company’s pipeline focus on RAS(ON) mutant-selective inhibitors, including RMC-0708 (Q61H) and RMC-8839 (G13C). For more information, please visit www.revmed.com and follow us on LinkedIn.

Revolution Medicines Media & Investor Contact:
media@revmed.com
investors@revmed.com

FAQ

When is the Revolution Medicines (RVMD) investor webcast on RASolute 302 Phase 3 results?

The investor webcast is scheduled for Sunday, May 31, 2026 at 7:00 p.m. ET. According to Revolution Medicines, senior management will discuss positive Phase 3 RASolute 302 results for daraxonrasib after their presentation at the 2026 ASCO Annual Meeting.

How can investors access the May 31, 2026 Revolution Medicines (RVMD) RASolute 302 webcast?

Investors can access the live and archived webcast through Revolution Medicines’ investor relations events and presentations webpage. According to Revolution Medicines, a replay of the May 31, 2026 discussion will remain available on the company’s website for at least 14 days.

What will Revolution Medicines (RVMD) discuss about RASolute 302 at the May 31, 2026 webcast?

The webcast will cover positive Phase 3 RASolute 302 clinical trial results for daraxonrasib in metastatic PDAC. According to Revolution Medicines, senior management will review data presented in the Plenary Session at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting.

Which patient population is included in the RASolute 302 trial discussed by Revolution Medicines (RVMD)?

The RASolute 302 trial evaluates daraxonrasib in previously treated metastatic pancreatic ductal adenocarcinoma (PDAC) patients. According to Revolution Medicines, these patients have RAS-addicted cancers and are the focus of the positive Phase 3 data being discussed on the May 31, 2026 webcast.

What is daraxonrasib in the Revolution Medicines (RVMD) RASolute 302 Phase 3 study?

Daraxonrasib is a targeted therapy candidate evaluated in the Phase 3 RASolute 302 trial. According to Revolution Medicines, the study involves patients with previously treated metastatic PDAC and has generated positive results to be discussed during the May 31, 2026 investor webcast.

Will a replay be available for the Revolution Medicines (RVMD) RASolute 302 investor webcast?

Yes, a replay of the investor webcast will be available on the company’s website. According to Revolution Medicines, the archived RASolute 302 discussion can be accessed via the investor relations events page for at least 14 days after the May 31, 2026 event.